Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 11/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21131804 | 0.94 | AR (0.38) | CYP11B1CYP11B2ARALDH1A1LMNA | |
| SCHEMBL21132033 | 0.91 | KIF11 (0.42) | CYP11B1CYP11B2ARRXRARXRG | |
| SCHEMBL21131417 | 0.90 | CYP11B1 (0.40) | CYP11B1CYP11B2ARRXRARXRG | |
| SCHEMBL20923736 | 0.90 | CYP11B1 (0.40) | CYP11B1CYP11B2ALDH1A1LMNAHPGD | |
| SCHEMBL21131416 | 0.87 | AR (0.38) | CYP11B1CYP11B2ARALDH1A1LMNA | |
| SCHEMBL20114887 | 0.87 | CYP11B1 (0.35) | CYP11B1CYP11B2ARRXRAALDH1A1 | |
| SCHEMBL21132035 | 0.86 | KIF11 (0.39) | ARALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL21116870 | 0.86 | CYP11B1 (0.42) | CYP11B1CYP11B2ARRXRARXRG | |
| SCHEMBL21131388 | 0.85 | KIF11 (0.40) | ARSMN1; SMN2KIF11 | |
| SCHEMBL20849337 | 0.85 | CYP11B1 (0.36) | CYP11B1CYP11B2ARRXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11380849-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2022-07-05 | — | — | US | disclosed |
| EP-3478657-B1 | DICARBAZOLBIPHENYLDERIVATIVES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-20190198778-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11380849-B2 | Organic molecules for use in optoelectronic devices | OR10J3, NOX3, ORC3 | CYP11B1 1388/4885CYP11B2 1193/4885AR 912/4885 |
| US-20190198778-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | ORC3, OR10J3, NOX3 | CYP11B1 1457/4885CYP11B2 1360/4885AR 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.